Investors / Netherlands / Curie Capital
Curie Capital
Venture capital · Amsterdam, Netherlands · Europe
Curie Capital is a life sciences venture capital firm founded in 2018 and headquartered in Amsterdam. It invests in early-stage biotechnology, pharmaceutical and medical technology companies and supports them with syndicates, hires and network access.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechnologymedical technologydiagnosticstherapeuticsmedical devices
Your fit with Curie Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCurie Capital lists 7 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Seed, 33% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in Netherlands. It invests most often alongside BioGeneration Ventures, Brabant Development Agency (BOM) and Kurma Partners.
Counts come from funding rounds that name Curie Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 33% |
| Series B | 33% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 12th | 7 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 96th | 29% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| BioGeneration Ventures | 3 |
| Brabant Development Agency (BOM) | 3 |
| Kurma Partners | 3 |
| Angelini Ventures | 1 |
| Apollo Health Ventures | 1 |
| Biovance Capital | 1 |
| Fund+ | 1 |
| Hadean Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers7100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with BioGeneration Ventures
Compare Curie Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Curie Capital| Date | Company | Stage |
|---|---|---|
| 4 Dec 2025 | Seed | |
| 1 Dec 2025 | Series A | |
| 4 Feb 2025 | Series B |
Round details for Curie Capital
Amounts, full round histories and every co-investor in Curie Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
7 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Allero Therapeutics develops novel non-invasive and patient-friendly next generation immunotherapies for immune mediated disorders | Healthcare & Biotech | Portfolio page | ||
| Avidicure develops antibodies for patients with oncology and autoimmune diseases | Healthcare & Biotech | Portfolio page | ||
| Citryll develops therapies to treat immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs) | Healthcare & Biotech | Portfolio page | ||
| Cleara Biotech is a biopharmaceutical research and development company focused on developing peptide-based therapies against cancer and chronic diseases. | Healthcare & Biotech | Portfolio page | ||
| Laigo Bio develops targeted therapies using protein degradation technology | Healthcare & Biotech | Dec 2025Seed | Funding round | |
| Sirius Medical Systems develops and provides a real-time navigation system for breast surgeons | Healthcare & Biotech | Feb 2025Series B | Page + round | |
| Dec 2025Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- curiecapital.nl
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 4 Feb 2025
- Companies checked
- 7
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Curie Capital's profile as data
Pull Curie Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/curiecapital.nl
# also
GET /v1/firms/curiecapital.nl/portfolio
GET /v1/firms/curiecapital.nl/coinvestors
GET /v1/firms/curiecapital.nl/news